Isomorphic Labs, the AI drug discovery company aiming to transform medicine with its state-of-the-art drug design engine, has secured a substantial $2.1B in Series B funding. The round saw participation from a high-profile group of investors including Thrive Capital, Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund, signaling strong backing for its ambitious health mission.
The company, which builds on the Nobel-winning AlphaFold system, is developing technology designed to revolutionize how new drugs are created. Its interdisciplinary team is focused on advancing human health and ultimately achieving its goal to one day solve all disease.
